Trust in the U.S. Food and Drug Administration (FDA) declined after its approval of the controversial Alzheimer’s drug aducanumab. Three experts resigned amid allegations that the FDA had caved to industry pressure. Some argue that its credibility has reached a new low. These events should have prompted the FDA to pause, reflect, and work to repair its reputation. Instead, the
The District of Colorado recently dismissed a lawsuit against a Dutch cannabis company for lack of personal jurisdiction in a case that highlights two issues common to international litigation. Growcentia, Inc. v. Jemie B.V., Case No. 20-cv-2619-WJM-NYW (D. Colo. Aug. 10, 2021). The first concerns service of process (the complaint and summons) on foreign corporations
Most business purchase transactions we see in the cannabis space are structured to have a concept of “closing”, which I’ve described before here. Essentially, this means that the parties sign, there is some gap of time for them to take care of certain things, and then the business is sold. Today, I want to examine
Last year, we wrote a mini-series on the five most common causes of action we were seeing in the evolving world of cannabis litigation. Given that we’re seeing some other trends (I last wrote about defamation back in January), we’re going to continue on with another often-included cause of action: conversion. Introduction Conversion is defined
Watch HERE! Cannabis disputes are unique. They are typically more complex than disputes involving other industries and they are often “bet the business” affairs. Over the years, we have developed and prosecuted successful litigation strategies for many of our clients across the country and around the world. Harris Bricken litigators regularly advise cannabis and hemp
In a prior post, we discussed some of the emerging trends for cannabis-related companies that seek bankruptcy protection (click here to view the prior post). But, in the first instance, the question is whether a cannabis-related company can file for bankruptcy relief? This post will examine the first decision from Arizona in the case of
Certain states are better than others when it comes to lucrative ketamine ventures. Whether you’re a physician looking to open a clinic in the space, or if you’re a third party lay person or entity looking to fund or manage such a practice, you need to be on the look-out for states with strict corporate
Costa Rican legislators are set to reinitiate debate over a bill (Expediente N.° 21.388) to legalize hemp and medical cannabis. The bill was cleared by the Legislative Assembly’s Environment Commission last November, but its presentation to the assembly’s plenum has been delayed. The bill’s author is independent legislator Zoila Rosa Volio, an agronomist and lawyer,
For anyone who was unable to join our August 17th webinar, Cannabis in New York: The Marijuana Regulation and Taxation Act’s Impact on New York City, we’ve got you covered! Below, please find the full presentation for your viewing pleasure. You can download the transcript HERE. Stay up to date on cannabis in New York via the
Last week, the Food and Drug Administration (the “FDA”) maintained its strict and narrow position on the legality of cannabidiol (“CBD”) by rejecting two new dietary ingredient (“NDI”) notifications submitted by Charlotte’s Web and Irwin Naturals. Both companies sought agency clearance to market their full-spectrum hemp extract as “dietary supplements.” In its letters to these
